C-reactive protein as a prognostic factor for mortality in ruptured abdominal aortic aneurysms;Proteína C reactiva como factor pronóstico de mortalidad en los aneurismas de aorta abdominal rotos

Angiologia

Volumn 57, Issue 3, 2005, Pages 225-236

  Bohórquez Sierra, Juan Carlos ^a   Doiz Artazcoz E ^a   Ocana E ^a   Craven Bartle, A ^a   Rodriguez Pinero M ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Acute phase proteins; Aortic aneurysm; Atherosclerosis; C reactive protein; Inflammation; Ruptured

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANEURYSM SURGERY; AORTA CLAMPING; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FIBRINOGEN BLOOD LEVEL; HEMODYNAMICS; HUMAN; INFLAMMATION; LEUKOCYTE; MORTALITY; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

EID: 33646451674     PISSN: 00033170     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-3170(05)79328-7     Document Type: Article

References (25)

1. Heinrich J, Schulte H, Schoenfeld R, Koehler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemostasis 1995; 73: 379.
2. Ferreiros ER, Boissonnet CP, Pizarro R, Merletti PF, Corrado G, Cagide A, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999; 100: 1958-63.
3. Domanovits H, Schillinger M, Müllner M, Hölzenbein T, Janata K, Bayegan K, et al. Acute phase reactants in patients with abdominal aortic aneurysm. Atherosclerosis 2002; 163: 297-302.
4. Argimón JM, Jiménez J. Métodos de investigación clínica y epidemiológica. 2 ed. Barcelona: Harcourt; 1999.
5. Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. Br J Surg 2002; 89: 714-30.
6. Heller JA, Weinberg A, Arons R, Krishnasastry KV, Lyon RT, Deitch JS, et al. Two decades of abdominal aortic aneurysm repair: have we made any progress? J Vasc Surg 2000; 32: 1091-100.
7. Heikkinen M, Salenius JP, Auvinen O. Ruptured abdominal aortic aneurysm in a well-defined geographic area. J Vasc Surg 2002; 36: 291-6.
8. Kniemeyer HW, Reber PU, Kessler T, Beckmann H, Hakki H. Risk assessment in patients with ruptured abdominal aortic aneurysms. Acta Chir Belg 2002; 102: 176-82.
9. Farooq MM, Freischlag JA, Seabrook GR, Moon MR, Aprahamian C, Towne JB. Effect of the duration of symptoms, transport time, and length of emergency room stay on morbidity and mortality in patients with ruptured abdominal aortic aneurysms. Surgery 1996; 119: 9-14.
10. Ernst CB. Abdominal aortic aneurysms. N Engl J Med 1993; 328: 1167-71.
11. Chen JC, Hildebrand HD, Salvian AJ, Taylor DC, Strandberg S, Myckatyn TM, et al. Predictors of death in nonruptured and ruptured abdominal aortic aneurysms. J Vasc Surg 1996; 24: 614-20.
12. Noel AA, Gloviczki P, Cherry KJ Jr, Bower TC, Panneton JM, Mozes GI, et al. Ruptured abdominal aortic aneurysms: the excessive mortality rate of conventional repair. J Vasc Surg 2001; 34: 41-6.
13. Van Dongen HP, Leusink JA, Moll FL, Brons FM, de Boer A. Ruptured abdominal aortic aneurysms: factors influencing postoperative mortality and long-term survival. Eur J Vasc Endovasc Surg 1998; 15: 62-6.
14. Koskas F, Kieffer E. Surgery for ruptured abdominal aortic aneurysm: early and late results of a prospective study by the AURC in 1989. Ann Vasc Surg 1997; 11: 90-9.
15. Hatori N, Yoshizu H, Shimiu M, Hinokiyama K, Takeshima S, Kimura T, et al. Prognostic factors in the surgical treatment of ruptured abdominal aortic aneurysms. Surg Today 2000; 30: 785-90.
16. Cronenwett JL, Krupski WC. Abdominal aortic aneurysm. Overview. In Rutherford RB, ed. Vascular surgery. 5 ed. Philadelphia: WB Saunders; 2000. p. 1241-6.
17. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
18. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit 2002; 8: 5-12.
19. Folsom AR, Pankow JS, Tracy RP, Arnet DK, Peacock JM, Hong Y, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88: 112.
20. Pasceri V, Chang J, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractan protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-4.
21. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-6.
22. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardia infarction. Circulation 1997; 95: 97-103.
23. Vainas T, Lubbers T, Stassen FRM, Herngreen SB, Van Dieijen-Visser MP, Bruggeman CA, et al. Serum C-reactive protein level is associated with aortic aneurysm size and may be produced by aneurysmal tissue. Circulation 2003; 107: 1103-5.
24. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-51.
25. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.